Nevro (NYSE:NVRO) Releases Quarterly Earnings Results, Beats Estimates By $0.32 EPS

Nevro (NYSE:NVRO) released its quarterly earnings results on Tuesday. The medical equipment provider reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($1.02) by $0.32, Briefing.com reports. Nevro had a negative net margin of 21.69% and a negative return on equity of 30.22%. The business had revenue of $101.90 million for the quarter, compared to the consensus estimate of $97.90 million. During the same period last year, the firm earned ($0.98) earnings per share. The company’s quarterly revenue was up 5.8% on a year-over-year basis.

Nevro Price Performance

Shares of NYSE:NVRO traded up $0.06 during trading hours on Friday, hitting $10.57. 43,753 shares of the company’s stock traded hands, compared to its average volume of 500,941. The company has a debt-to-equity ratio of 0.72, a quick ratio of 4.94 and a current ratio of 6.37. The company has a market cap of $387.72 million, a price-to-earnings ratio of -4.09 and a beta of 0.96. Nevro has a 52 week low of $10.02 and a 52 week high of $28.89. The company’s fifty day simple moving average is $13.04 and its two-hundred day simple moving average is $16.19.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on NVRO. StockNews.com upgraded Nevro from a “sell” rating to a “hold” rating in a research report on Friday, March 1st. Oppenheimer cut shares of Nevro from an “outperform” rating to a “market perform” rating in a report on Thursday, February 22nd. Mizuho dropped their price objective on shares of Nevro from $20.00 to $16.00 and set a “neutral” rating on the stock in a research note on Thursday, April 11th. Royal Bank of Canada reduced their price objective on shares of Nevro from $18.00 to $16.00 and set a “sector perform” rating for the company in a research report on Monday, April 15th. Finally, Citigroup reduced their price objective on Nevro from $18.00 to $16.00 and set a “neutral” rating for the company in a research note on Wednesday, April 3rd. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating and one has given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $20.00.

Nevro Company Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.